Anti-CTLA-4 and anti-PD-1/PD-L1 ICIs have been extremely successful for aggressive cancers such as advanced melanoma and non-small cell lung cancer (NSCLC) (18–20), and there is growing interest in the utility of ICIs as a potential treatment for glioblastoma. Here, CTLA4 is linked to non-small cell lung carcinoma.